CoChat

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

Open access
McClung, Michael R, Boonen, Steven, Törring, Ove, Roux, Christian, Rizzoli, René, Bone, Henry G, Benhamou, Claude-Laurent, Lems, Willem F, Minisola, Salvatore, Halse, Johan, Hoeck, Hans C, Eastell, Richard, Wang, Andrea, Siddhanti, Suresh, Cummings, Steven R · 2012 · Journal of Bone and Mineral Research
Cited by 154

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that the efficacy of antiresorptives on fractures might differ by patients' characteristics, such as age, bone mineral density (BMD), and fracture history. In the FREEDOM study, 7808 women aged 60 to 90 years with osteoporosis were randomly assigned to receive subcutaneous injections of denosumab (60 mg) or placebo every 6 months for 3 years. New vertebral and nonvertebral fractures were radiologically confirmed. Subgroup analyses described in this article were prospectively planned before study unblinding to evaluate the effect of denosumab on new vertebral and nonvertebral fractures across various subgroups. Compared with placebo, denosumab decreased the risk of new vertebral fractures in the overall study population over 3 years. This effect did not significantly differ for any of the nine subgroups analyzed (p > 0.09 for all potential interactions). Denosumab also reduced all nonvertebral fractures by 20% in the full study cohort over 3 years. This risk reduction was statistically significant in women with a baseline femoral neck BMD T-score ≤ −2.5 but not in those with a T-score > −2.5; in those with a body mass index (BMI) < 25 kg/m2 but not ≥ 25 kg/m2; and in those without but not with a prevalent vertebral fracture. These differential treatment effects were not explained by differences in BMD responses to denosumab. Denosumab 60 mg administered every 6 months for 3 years in women with osteoporosis reduced the risk of new vertebral fractures to a similar degree in all subgroups. The effect of denosumab on nonvertebral fracture risk differed by femoral neck BMD, BMI, and prevalent vertebral fracture at baseline. © 2012 American Society for Bone and Mineral Research

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jbmr.536

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 154

Metadata

Authors
McClung, M. R., Boonen, S., Törring, O., Roux, C., Rizzoli, R., Bone, H. G., Benhamou, C.-L., Lems, W. F., Minisola, S., Halse, J., Hoeck, H. C., Eastell, R., Wang, A., Siddhanti, S., & Cummings, S. R.
Venue
Journal of Bone and Mineral Research
Published
2011-10-04
Volume
27
Issue
1
Pages
211-218
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W1974865907
Cited by
154
References
6
FWCI
13.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. https://app.cochat.ai/papers/10.1002/jbmr.536
The paper
McClung, M. R., Boonen, S., Törring, O., Roux, C., Rizzoli, R., Bone, H. G., Benhamou, C.-L., Lems, W. F., Minisola, S., Halse, J., Hoeck, H. C., Eastell, R., Wang, A., Siddhanti, S., & Cummings, S. R. (2012). Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.536

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.